Literature DB >> 20511190

Evaluation of retinoic acid therapy for OTX2-positive medulloblastomas.

Renyuan Bai1, I-Mei Siu, Betty M Tyler, Verena Staedtke, Gary L Gallia, Gregory J Riggins.   

Abstract

The homeobox transcription factor OTX2 plays an essential role during embryonic brain development. It is normally silenced in the adult brain, but is overexpressed by genomic amplification or other mechanisms in the majority of medulloblastomas (MBs). Retinoic acids (RAs) can suppress OTX2 expression and inhibit MB growth. In this study, 9-cis RA most potently inhibited MB cell growth. 9-cis RA functions through the downregulation of OTX2 expression, which subsequently induces neuronal differentiation of OTX2-expressing cells. Treatment with 9-cis RA reduced the growth of D425 flank xenograft tumors in mice. In an intracranial model, however, MB tumors showed resistance to 9-cis RA treatment, and we implicated fibroblast growth factor (FGF) as a potential mediator of resistance to RA therapy. These findings suggest a mechanism for RA-mediated anti-tumor effect on OTX2-positive MB cells and indicate that therapeutic targeting of OTX2 might be effective if FGF pathway-mediated resistance can be overcome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20511190      PMCID: PMC2940451          DOI: 10.1093/neuonc/nop062

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  29 in total

1.  Genes differentially expressed in medulloblastoma and fetal brain.

Authors:  E M Michiels; E Oussoren; M Van Groenigen; E Pauws; P M Bossuyt; P A Voûte; F Baas
Journal:  Physiol Genomics       Date:  1999-08-31       Impact factor: 3.107

2.  Interleukin-2 and 13-cis retinoic acid as maintenance therapy in advanced ovarian cancer.

Authors:  Francesco Recchia; Gaetano Saggio; Alisia Cesta; Giampiero Candeloro; Antonio Nuzzo; Marco Lombardo; Gaspare Carta; Silvio Rea
Journal:  Int J Oncol       Date:  2005-10       Impact factor: 5.650

3.  The vitamin A analogues: 13-cis retinoic acid, 9-cis retinoic acid, and Ro 13-6307 inhibit neuroblastoma tumour growth in vivo.

Authors:  F Ponthan; P Borgström; M Hassan; E Wassberg; C P Redfern; P Kogner
Journal:  Med Pediatr Oncol       Date:  2001-01

Review 4.  Understanding the cognitive impact on children who are treated for medulloblastoma.

Authors:  Shawna L Palmer; Wilburn E Reddick; Amar Gajjar
Journal:  J Pediatr Psychol       Date:  2007-02-28

5.  Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid.

Authors:  Chunhui Di; Shaoxi Liao; David C Adamson; Timothy J Parrett; Daniel K Broderick; Qun Shi; Christoph Lengauer; Jordan M Cummins; Victor E Velculescu; Daniel W Fults; Roger E McLendon; Darell D Bigner; Hai Yan
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

Review 6.  The WHO classification of tumors of the nervous system.

Authors:  Paul Kleihues; David N Louis; Bernd W Scheithauer; Lucy B Rorke; Guido Reifenberger; Peter C Burger; Webster K Cavenee
Journal:  J Neuropathol Exp Neurol       Date:  2002-03       Impact factor: 3.685

7.  Retinoic acid is detected at relatively high levels in the CNS of adult rats.

Authors:  Elizabeth A Werner; Hector F Deluca
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-03       Impact factor: 4.310

8.  Separation of retinoid-induced epidermal and dermal thickening from skin irritation.

Authors:  James Varani; Helene Fligiel; Jian Zhang; Muhammad Nadeem Aslam; Yi Lu; Lindsay A Dehne; Evan T Keller
Journal:  Arch Dermatol Res       Date:  2003-10-16       Impact factor: 3.017

9.  OTX1 and OTX2 expression correlates with the clinicopathologic classification of medulloblastomas.

Authors:  Talitha de Haas; Esmeralda Oussoren; Wieslawa Grajkowska; Marta Perek-Polnik; Mara Popovic; Lorna Zadravec-Zaletel; Marzia Perera; Giorgio Corte; Oliver Wirths; Peter van Sluis; Torsten Pietsch; Dirk Troost; Frank Baas; Rogier Versteeg; Marcel Kool
Journal:  J Neuropathol Exp Neurol       Date:  2006-02       Impact factor: 3.685

Review 10.  Alitretinoin: a comprehensive review.

Authors:  Caleb Cheng; Jason Michaels; Noah Scheinfeld
Journal:  Expert Opin Investig Drugs       Date:  2008-03       Impact factor: 6.206

View more
  11 in total

1.  Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis.

Authors:  Ren-Yuan Bai; Verena Staedtke; Charles M Rudin; Fred Bunz; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2014-09-24       Impact factor: 12.300

2.  Synchronous glioblastoma and medulloblastoma in a child with mismatch repair mutation.

Authors:  Nisreen Amayiri; Maysa Al-Hussaini; Maisa Swaidan; Imad Jaradat; Monther Qandeel; Uri Tabori; Cynthia Hawkins; Awni Musharbash; Khulood Alsaad; Eric Bouffet
Journal:  Childs Nerv Syst       Date:  2015-08-21       Impact factor: 1.475

3.  UAB30, a novel RXR agonist, decreases tumorigenesis and leptomeningeal disease in group 3 medulloblastoma patient-derived xenografts.

Authors:  Evan F Garner; Laura L Stafman; Adele P Williams; Jamie M Aye; Caroline Goolsby; Venkatram R Atigadda; Blake P Moore; Li Nan; Jerry E Stewart; Anita B Hjelmeland; Gregory K Friedman; Elizabeth A Beierle
Journal:  J Neurooncol       Date:  2018-08-21       Impact factor: 4.130

4.  Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme.

Authors:  Ren-Yuan Bai; Verena Staedtke; Colette M Aprhys; Gary L Gallia; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2011-07-15       Impact factor: 12.300

5.  Evaluation of a DNA demethylating agent in combination with all-trans retinoic acid for IDH1-mutant gliomas.

Authors:  Marina da Costa Rosa; Alex Shimura Yamashita; Gregory J Riggins
Journal:  Neuro Oncol       Date:  2022-05-04       Impact factor: 12.300

6.  Pharmacologic Wnt Inhibition Reduces Proliferation, Survival, and Clonogenicity of Glioblastoma Cells.

Authors:  Ulf D Kahlert; Abigail K Suwala; Katharina Koch; Manabu Natsumeda; Brent A Orr; Masanori Hayashi; Jarek Maciaczyk; Charles G Eberhart
Journal:  J Neuropathol Exp Neurol       Date:  2015-09       Impact factor: 3.685

7.  OTX2 represses myogenic and neuronal differentiation in medulloblastoma cells.

Authors:  Ren-Yuan Bai; Verena Staedtke; Hart G Lidov; Charles G Eberhart; Gregory J Riggins
Journal:  Cancer Res       Date:  2012-09-17       Impact factor: 12.701

8.  Chromatin accessibility mapping identifies mediators of basal transcription and retinoid-induced repression of OTX2 in medulloblastoma.

Authors:  Matthew Wortham; Changcun Guo; Monica Zhang; Lingyun Song; Bum-Kyu Lee; Vishwanath R Iyer; Terrence S Furey; Gregory E Crawford; Hai Yan; Yiping He
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

9.  Enhanced inhibition of clonogenic survival of human medulloblastoma cells by multimodal treatment with ionizing irradiation, epigenetic modifiers, and differentiation-inducing drugs.

Authors:  Ina Patties; Rolf-Dieter Kortmann; Franziska Menzel; Annegret Glasow
Journal:  J Exp Clin Cancer Res       Date:  2016-06-17

10.  Characterization of a novel OTX2-driven stem cell program in Group 3 and Group 4 medulloblastoma.

Authors:  Margaret Stromecki; Nazanin Tatari; Ludivine Coudière Morrison; Ravinder Kaur; Jamie Zagozewski; Gareth Palidwor; Vijay Ramaswamy; Patryk Skowron; Matthias Wölfl; Till Milde; Marc R Del Bigio; Michael D Taylor; Tamra E Werbowetski-Ogilvie
Journal:  Mol Oncol       Date:  2018-03-01       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.